Nuorodos
19 iš 19 · ~51 min. skaitymo
1. Bozic.I., Reiter, J.G., Allen, B., et al. Evolutionary dynamics of cancer in response to targeted combination therapy. Elife, 2013, 2 e00747
2. Stupp, R., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England J. Med, 2005, 352 (22), 987996
3. Stupp, R., Hegi, M.D., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5year analysis of the EORTCNCIC trial. Lancet Oncol., 2009, May; 10(5): 45966. .
4. Iwadate, Y. et al. Promising survival for patients with glioblastoma multiforme treated with individualized chemotherapy based on in vitro drug sensitivity testing. British Journal of Cancer, 2003, Vol. 89, 18961900
5. Hegi, M.E, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. New England J. of Med, 2005, 352(10), 9971003
6. Preusser, M. et al. Anti06methylguanine –methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: Observer variability and lack of association with patient survival impede its use as a clinical biomarker. Brain Pathol. 2008, 18 (4) 52032
7. Vlassenbroeck, I. et al. Validation of realtime methylationspecific PCR to determine 06MethylguanineDNA methylationspecific PCR to determine 06 methylguanineDNA methyltransferase gene promoter methylation in glioma. Journal of Mol. Diagn. 2008, 10 (4) 33237
8. Tanaka, S., et al. Individual adjuvant therapy for malignant gliomas based on 06 methylguanineDNAmethyltransferase messenger RNA quantitation by realtime reversetranscription polymerase chainreaction. Oncol. Rep., 2008, 20 (1) 16571
9. Herrlinger, U., Schaefer, N., Steinbach, J. P., et al. Bevacizumab, irinotecan, and radiotherapy versus standard temozolomide and radiotherapy in newly diagnosed, MGMTnonmethylated glioblastoma patients: First results from the randomized multicenter GLARIUS trial. J. Clinical Oncol., 31, 2013 (Suppl: abstract LBA2000).
10. Kast, R.E., Boockvar, J. A., Bruening, A., et al. A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care. Oncotarget, 2013, 4(4), 502530
11. Bowles, A. P. Jr. et al. Use of verapamil to enhance the antiproliferative activity of BCNU in human glioma cells: an in vitro and in vivo study. Journal of Neurosurgery, 1990, Vol. 73, pp. 248253
12. Belpomme, D., et al. Verapamil increases the survival of patients with anthracyclineresistant metastatic breast carcinoma. Annals of Oncology, 2000, Vol. 22, pp. 14711476
13. Millward, M. J., Cantwell, B. M. J., et al. Oral verapamil with chemotherapy for advanced nonsmall cell lung cancer: a randomized study. Br. J. Cancer. 1993. 67(5): 103135
14. Figueredo, A., et al. Addition of verapamil and tamoxifen to the initial chemotherapy of small cell lung cancer: A phase I/II study. Cancer, 1990, Vol. 65, pp. 18951902
15. Huang, C. X. et al. Growth inhibition of epidermal growth factorstimulated human glioblastoma cells by nicardipine in vitro. Hunan Yi Ke Da Xue Xue Bao, 2001, 26, 211214 (article in Chinese but abstract on PubMed)
16. . Durmaz, R, et al. The effects of anticancer drugs in combination with nimodipine and verapamil on cultured cells. Clinical Neurology & Neurosurgery, 1999, 101, 238244
17. Loo, T.W. & Clarke, D. M. Blockage of drug resistance in vitro by disulfiram, a drug used to treat alcoholism. J. Natl. Cancer Instit., 2000, 92(11), 898902
18. Loo, T.W. Bartlett, M.C., & Clarke, D.M. Disulfiram metabolites permanently inactivate the human multidrug resistance Pglycoprotein. Mol. Pharm.,2004, 1(6), 426433
19. Luciani, F., Spada, M., De Milito, A., et al. Effect of proton pump inhibitor pretreatment on the resistance of solid tumors to cytotoxic drugs. Journal of the National Cancer Institute, 2004, 96(22), 170213
20. Shao, Y. M., Ayaesh, S., & Stein, W. D. Mutually cooperative interactions between modulators of Pglycoprotein. Biochem Biophys Acta., 1997, 1360(1), 3038
21. Soma, M. R., et al. Simvastatin, an inhibitor of cholesterol biosynthesis, shows a synergistic effect with N, N'bis (2chloroethyl)Nnitrosourea and betainterferon on human glioma cells. Cancer Research, 1992, Vol. 52, pp. 43484355.
22. Soritau, O. Tomuleasa, C., Aldea, M., et al. Metformin plus temozolomidebased chemotherapy as adjuvant treatment for WHO grade III and IV malignant gliomas. J. Buon, 2011, 16(2), 28289
23. Briceno, E., et al. Therapy of glioblastoma multiforme improved by the antimutagenic chloroquine. Neurosurgical Focus, 2003, 14(2), e3
24. Sotelo, J., et al. Adding chloroquine to conventional treatment for glioblastoma multiforme: A randomized doubleblind, placebocontrolled trial. Annals of Internal Medicine, 2006, Vol. 144 (5), 337343
25. Briceno, E., et al. Institutional experience with chloroquine as an adjuvant to the therapy for glioblastoma multiforme. Surgical Neurology, 2007, 67(4), 388391
26. Black, K. L., Yin, D., Ong, J. M., et al. PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model. Brain Res, 2008, 290302
27. Kast. R. E., & Focosi, D. Three paths to better tyrosine kinase inhibition behind the bloodbrain barrier in treating chronic myelogenous leukemia and glioblastoma with imatinib. Trans. Oncol. 2010, 3(1), 1315
28. Brock, C. S., et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Research, 1998, Vol. 58, pp. 43634367
29. Clarke, J. L., Iwamoto, F. M., Sul, J., et al. Randomized phase II trial of chemoradiotherapy followed by either dosedense or metronomic temozolomide for newly diagnosed glioblastoma. J. Clin Oncol., 2009, 27(23): 386167
30. Gilbert, M. R., Wang, M. Aldape, R. et al. RTOG 0525: A randomized phase III trial comparing standard adjuvant temozolomide with a dosedense schedule with newly diagnosed glioblastoma. Proceedings of the 2011 ASCO meeting, Abstract # 2006
31. Brada, M. , Stenning, S., Gabe, R., et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent highgrade glioma. J. Clin. Oncol, 2010, 28(30), 46018
32. Buttolo, L., et al. Alternative schedules of adjuvant temozolomide in glioblastoma multiforme: A 6year experience. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings. Part I. Vol. 24, No. 18S, Abstract 1511
33. Wick, W., et al. One week on/one week off: a novel active regimen of temozolomide. Neurology, 2004, 62, 21132115
34. Wick, W., & Weller, M., How lymphotoxic is doseintensified temozolomide? The glioblastoma experience. J. Clin Oncol., 2005, 20(18), 42354236
35. Galldiks, N., Berhorn, T., Blau, T., et al. “ One week onone week off “efficacy and side effects of doseintensified temozolomide chemotherapy: experiences of a single center. J. of Neurooncology, 2013, 112, 209215
36. Taal, W., Segersvan Rjn, J. M., Kros, J. M., et al. Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study. J. Neurooncology, 2012, 108(1), 195200
37. Man. S., et al. Antitumor effects in mice of lowdose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Research, 2002, Vol. 62, 27312735
38. Browder, T., et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drugresistant cancer. Cancer Research, 2000, Vol. 60, pp. 18781886
39. Kong, D. S., et al. A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomiderefractory glioblastoma. Oncol. Rep. 2006, 16(5), 11171121
40. Perry, J. R., et al. Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: The “Rescue” approach. Cancer (2008), 113 (8), 215257
41. Ney, D. et al. Phase II trial of continuous lowdose temozolomide for patients with recurrent malignant glioma. Proceedings of the 2008 meeting of the Society for NeuroOncology, Abstract MA56
42. Namm, DH, et al. Phase II trial of lowdose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma. Proceedings of the 2008 meeting of the Society of NeuroOncology, Abstract MA89
43. Omuro, A. Chan, T.A., Abrey, L. E., et al. Phase II trial of continuous lowdose temozolomide for patients with recurrent malignant glioma. Neurooncology,2013, 15(2), 242250.
44. Tuettenberg, J., et al. Continuous lowdose chemotherapy plus inhibition of cyclooxygenase2 as an antiangiogenic therapy of glioblastoma multiforme. J. Cancer Research & Clinical Oncology, 2005, 112391244
45. Scheda, A., Finjap, J. K., et al. Efficacy of different regimens of adjuvant radiochemotherapy for treatment of glioblastoma. Tumori, 2007, 93(1), 3136
46. Stockhammer, F. Misch, M., Koch, A., et al. Continuous lowdose temozolomide and celecoxib in recurrent glioblastoma. J. Neurooncol. 2010, Epub, May 06.
47. Khan, R. B., et al. A phase II study of extended lowdose temozolomide in recurrent malignant gliomas. Neurooncology, 2002, 4, 3943
48. Balducci, M., D’Agostino, G. R., Manfrida, S., et al. Radiotherapy and concomitant temozolomide during the first and last weeks in high grade gliomas: long term analysis of a phase II study. J. Neurooncol., 2010, 97(1), 95100
49. Brown, I., & Edwards, I. T. The potential benefit of neoadjuvant and extended adjuvant temozolomide with the Stuppregimen in the treatment of glioblastoma. 2009 Meeting of the Society for NeuroOncology, Abstract P185
50-99
50. Bhandari, M., Gandhi, A.K., Julka, P. K., et al. Comparative study of six cycles versus twelve cycles of adjuvant temozolomide post concurrent chemoradiation in newly diagnosed glioblastoma . Proceedings of the 2013 ASCO Meeting, Abstract # e13034
51. Roldan,G. B., Singh, A. D., & Easaw, J. C. Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme. J Neurooncology, 2012, 108(1), 1731737
52. Glas, M., Happold, C., et al. Longterm survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. J.Clin. Oncol. 27(8), 12571261
53. Prados, M. D., et al. Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study. Neuro oncology, 2004, 6, pp. 3337
54. Brem, H. et al. Placebocontrolled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas: The Polymer BrainTumor Treatment Group. Lancet, 1995, Vol. 345 (8956), 10081012
55. Westphal, M. et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neurooncology, 2003, 5, 7988
56. Pan, E., Mitchell, S. B., & Tsai, J. S. A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients. J. Neurooncol., 2008, 88, 353357
57. McGirt, M. J., Khoi, D., et al. Gliadel BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J. Neurosurg., 2009, 110, 583588
58. Affronti, M. L., Heery, C. R., et al. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. Cancer, 2009, 115: 3501 3511
59. Quinn, J .A., Jiang, S.X., Carter J., et al. Phase II trial of gliadel plus 06 benzylguanine in adults with recurrent glioblastoma multiforme. Clin Cancer Res., 2009, 15(3), 106468
60. Limentani, S. A., Asher, A., Heafner, M., e al. A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme. J. Neurooncol, 2005, 72(3), 241244
61. Brandes, A. A., et al. Firstline chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma Multiforme: A phase II study of the Gruppo Italiano Cooperativo di NeuroOncologia. Journal of Clinical Oncology, 2004, 22, pp. 15981604
62. Silvani, A., et al. Phase II trial of cisplatin plus temozolomide, in recurrent and progressive glioma patients. Journal of Neurooncology, 2003, 66, 203208
63. Mohin, G., et al. Intracarotid chemo followed by radiation with concomitant temozolomide (TMZ) and subsequent maintenance TMZ therapy in patients with glioblastoma multiforme. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings. Part I. Vol. 24, No. 18S, Abstract 1554
64. Newlands, E.S., et al. Phase I study of temozolomide (TMZ) combined with procarbazine (PCB) in patients with gliomas. British Journal of Cancer, 2003, 89, 248251.
65. Motomura, K., Natsume, A., Kishida, Y., et al. Benefits of interferonbeta and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter : A multicenter study. Cancer, 2011, 117(8), 172130
66. Groves, M.D., et al., A phase II study of temozolomide plus pegylated interferon alfa2b for recurrent anaplastic glioma and glioblastoma multiforme. 2005 meeting of the American Society of Clinical Oncology, Abstract #1519
67. Vredenburgh, J.J., Desjardins, A., Reardon, D. A., et al. The addition of bevacizumab to the standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin. Cancer Res., 2011, April 29. (Epub ahead of print)
68. Narayana, A., et al. Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed highgrade glioma. Int. J. Radiation Oncology Bio. Phys. 2008, 72 (2) 38389
69. Lai, A., Tran A., Nghiemphu, P. L., et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J. Cln. Oncol., 2011, 29(2), 1428
70. Genentech Press Release, June 1, 2013. Genentech announces final phase III study results of Avastin plus radiotherapy and Chemotherapy in People with an Aggressive form of brain cancer.
71. Plenary Session of ASCO 2013. RTOG0825: Phase III doubleblind placebo controlled trial evaluating bevacizumab (BEV) in patients with newly diagnosed glioblastoma (GBM). J. Clin. Oncol, 2013, 13 (supplement: abstract #1)
72. Brown, P. D., et al. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group study NO177. J. Clin. Oncol. 2008,26:56035609
73. Prados, M. D., et al. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J. Clin. Oncol. 2009, 27(4): 579584
74. Peereboom, D. M., Shepard, D. R., Ahluwalia, M. S., et al. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. J. Neurooncol. 2010, 98(1), 0.9399
75. Neyns, B., et al. A multicenter stratified phase II study of cetuximab for the treatment of patients with recurrent highgrade glioma. Proceedings of the 2008 ASCO meeting, Abstract # 2017
76. Combs, S. E., et al. Erbitux (Cetuximab) plus temozolomide as radiochemotherapy for primary glioblastoma (GERT): Interim results of a phase I/II study. Int. J. Rad. Oncol. Biol. Physics, 2008, 72(1) Suppl. 1: Pages S10S11
77. HaasKogan, D. A., et al. Epidermal growth factor receptor, protein kinase PKB/AKT, and glioma response to erlotinib. Journal of the National Cancer Institute, 2005, 97 (12), 880887
78. Mellinghoff, I. K., et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med., 2005, 353 (19), 201224
79. Reardon, D. A., et al. Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clinical Cancer Research, 2006, 12 (3 Pt. 1) 860868. 80. Doherty, L., et al. Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology, 2006, 67(1), 156158
81. Reardon, D. A., Desjardins, A., Vredenburgh, J. J., et al. Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J. Neurooncol. 2010, 96(2), 219230
82. Cemeus, C., et al. Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status. J Neurooncol, 2008. 90(1), 917
83. Chakravarti, A., et al. Insulinlike growth factor receptor I mediates resistance to antiepidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3kinase signaling. Cancer Research, 2002, Vol. 62, 200207
84. Wen, P. Y., et al. Phase I study of STI 571 (Gleevec) for patients with recurrent malignant gliomas and meningiomas (NABTC 9908). Proceedings of the American Society of Clinical Oncology, 2002, Abstract # 288
85. Raymond, E., et al. Multicentre phase II study of imatinib mesylate in patients with recurrent glioblastoma: An EORTC: NDDG/BTG Intergroup study. Proceedings of the American Society of Clinical Oncology, 2004, Abstract #1501
86. Dresemann, G., et al. Imatinib (STI571) plus hydroxyurea: Safety and efficacy in pretreated progressive glioblastoma multiforme patients. Proceedings of the American Society of Clinical Oncology, 2004, Abstract #1550
87. Dreseman, G., Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. Annals of Oncology, 2005, epub access, July 20, 2005
88. Reardon. D. A., et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. Journal of Clinical Oncology, 2005, 23(36), 93599368
89. Reardon, D. A., Dresemann, G., Tailibert, S., et al. Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. Br. J. Cancer, 2009, 101, 19952004.
90. Viola, F. S., et al. A phase II trial of high dose imatinib in recurrent glioblastoma multiforme with platelet derived growth factor receptor expression. J. of Clin Oncology, 2007 25(18S), Abstract No. 2056
91. Baumann, F. et al. Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme. J. Neurooncology, 2004, 67(12), 1912001
92. Chang, S.M, et al. Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. Int. .J. Radiation Oncology, Biol & Phys., 2004, 60 (2), 353357
93. Groves, M.D., et al. A North American brain tumor consortium phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. Journal of Neurooncology, 2007, 81(3)
94. Glass, J. et al. Phase I/II study of carboplatin and thalidomide in recurrent glioblastoma. Proceedings of the American Society of Clinical Oncology, 1999, Abstract #551
95. Fine, H.A., Wen, P.Y., Maher, E. A., et al. Phase II trial of thalidomide and carmustine for patients with recurrent highgrade gliomas. J. Clin. Oncol., 2003, 21 (12), 22992304
96. Jaeckle, K. A., et al. Phase II evaluation of temozolomide and 13cisretinoic acid for the treatment of recurrent and progressive malignant glioma: A NABTC consortium study.
97. Butowski, N., et al., A phase II study of concurrent temozolomide and cisretinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma. Int. J. of Rad. Oncol., Biol., & Phys., 2005, 61(5), 14541459
98. Pitz, M.W., Lipson, M., Hosseini, B., et al. Extended adjuvant temozolomide with cisretinoic acid for adult glioblastoma. Current Oncology, 2012, 19(6), 30814
99. Yung, W. K. A. et al. Treatment of recurrent malignant gliomas with highdose 13 cisretinoic acid. Clinical Cancer Research, 1996 Vol. 2, pp. 19311935
100-149
100. See, S. J. et al. 13cisRetinoic acid in the treatment of recurrent glioblastoma multiforme. Neurooncology, 2004, 6, 253258
101. Wismeth, C., et al. Maintenance therapy with 13cis retinoic acid in highgrade glioma at complete response after firstline multimodal therapya phase II study. Journal of Neurooncology, 2004, 68, 7986
102. Couldwell, W. T., et al. Treatment of recurrent malignant gliomas with chronic oral highdose tamoxifen. Clinical Cancer Research, 1996, Vol. 2, pp. 619622
103. Robins, H.I., Won, M., Seiferheld, W. F., et al. Phase 2 trial of radiation plus highdose tamoxifen for glioblastoma multiforme. Neurooncology, 2006, 8,4752
104. Mastronardi, L. et al. Tamoxifen and carboplatin combinational treatment of highgrade gliomas. Results of a clinical trial on newly diagnosed patients. Journal of NeuroOncology, 1998, Vol. 38, pp. 5968
105. Puchner, M. J., et al. Surgery, tamoxifen, carboplatin, and radiotherapy in the treatment of newly diagnosed glioblastoma patients. Journal of Neurooncology, 2000, 49, 147155
106. Tang, P. et al. A phase II study of carboplatin and chronic highdose tamoxifen in patients with recurrent malignant glioma. Journal of Neurooncology, 2006, 78 (3), 311316
107. Vertosick, F. T. and Selker, R. G. The treatment of newly diagnosed glioblastoma multiforme using high dose tamoxifen (TMX), radiotherapy and conventional chemotherapy. Proceedings of the American Association for Cancer Research, 1997, Abstract # 2887
108. Napolitano, M. et al. Treatment of a supratentorial glioblastoma multiforme with radiotherapy and a combination of BCNU and tamoxifen: a phase II study. Journal of Neurooncology, 1999, Vol. 45, 229235
109. Beretta C. et al. Modified protocol with temozolomide in combination with tamoxifen as adjuvant chemotherapy after surgery of highgrade gliomas. Proceedings of the European Association for Neurooncology, 2002, Abstract No. 71
110. Spence, A.M., et al. Phase II study of concurrent continuous temozolomide (TMZ) and Tamoxifen (TMX) for recurrent malignant astrocytic gliomas. Journal of Neurooncology, 2004, 70 (1), 9195
111. Patel,S., DiBiase, S., Meisenberg, B., et al. Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high grade glioma. Intern. J. Radiation Oncology Biol Phys, (2012). Vol. 82(2), 73942
112. Di Cristofori, A., Carraba, G., Lanfranchi, G., et al. Continuous tamoxifen and dosedense temozolomide in recurrent glioblastoma. Anticancer Research, 2013, 33(8)m 338389
113. Preul, M. C., et al. Using proton magnetic resonance spectroscopic imaging to predict in vivo the response of recurrent malignant gliomas to tamoxifen chemotherapy. Neurosurgery, 2000, Vol. 46, 306318
114. Hercbergs, A. A., et al. Propylthiouracilinduced chemical hypothyroidism with highdose tamoxifen prolongs survival in recurrent highgrade glioma: A phase I/II study. Anticancer Research, 2003, Vol. 23, 617626
115. Mohammadianpanah, M., RazmjourGhalael, S., Shafizad, A., et al. Efficacy and safety of concurrent chemoradiation with weekly cisplatin +/ lowdose celecoxib in locally advanced undifferentiated nasopharyngeal carcinoma: a phase IIIII clinical trial. Journal of Cancer Research & Therapy, 2011, 7(4), 44247
116. Debucquoy, A., Roels, S., Goethals, L., et al. Double blind randomized phase II study with radiation + 5fluorouracil +/ celecoxib for resectable rectal cancer. Radiotherapy Oncology, 2009, 93(2), 27278
117. Pannulo, S. et al. Phase I/II trial of twicedaily temozolomide and celecoxib for treatment of relapsed malignant glioma: Final Data. Proceedings of the American Society of Clinical Oncology, 2006, Abstract No. 1519
118. Reardon, D.A., et al. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer, 2004, 103(2), 329338
119. Dang, C. T., et al. Potential role of selective Cox2 inhibitors in cancer management. Oncology, 2004, 16 (supplement 5) 3036
120. New, P. Cyclooxygenase in the treatment of glioma: Its complex role in signal transduction. Cancer Control, 2004, 11, 15216
121. Giglo, P., & Levin, V. Cyclooxygenase2 inhibitors in glioma therapy. American Journal of Therapeutics, 2004, 11, 141143
122. Beaney, R.P., et al., Therapeutic potential of antidepressants in malignant glioma: clinical experiment with chlorimipramine. Proceedings of the American Society of Clinical Oncology, 2005, Abstract #1535
123. Bili, A., Eguven, M. Oktem, G., et al. Potentiation of cytotoxicity by combination of imatinib and chlorimipramine in glioma. Int. J. Oncol, 2008, 32(4), 829839
124. Michelakis, E. D., Sutendra, G., Dromparis, P., et al. Metabolic modulation of glioblastoma with dichloroacetate. Science Translational Medicine, 2010, 2 (31), 18
125. Kumar, K., Wigfield, S., Gee, H. E., et al. Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts. Journal of Molecular Medicine, 2013, 91(6), 74958
126. Ishiguro, T., Ishiguro, M., Ishiguro, R. & Iwai, S. Cotreatment with dichloroacetate and omeprazole exhibits a synergistic antiproliferative effect. Oncology Letters, 2012, 3, 726728
127. Spugnini, E. P., Baldi, A., Buglioni, S., et al. Lansoprazole as a rescue agent in chemoresistant tumors: a phase I/II study in companion animals with spontaneously occurring tumors. Journal of Translational Medicine, 2011, 9 (221) (Dec. 28)
128. Hu, X., Wang, B., Sun, S., et al. Intermittent high dose proton pump inhibitor improves progression free survival as compared to standard chemotherapy in the first line treatment of patients with metastatic breast cancer. Cancer Research, 2012, 72 (24 Supplement), Abstract nr p61101
129. Galanis, E., et al. Phase II trial of vorinostat in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group study. J. Clin. Oncol. 2009, 27(12): 2052 2058
130. Peters, K.B., Vredenburgh, J. J., Desjardins. A. et al. Vorinostat, temozolomide, and bevacizumab for patients with recurrent glioblastoma: A phase I/II trial. 2012 ASCO meeting, Abstract #2027
131. DeBoer, R., et al. Response of an adult patient with pineoblastoma to vorinostat and retinoic acid. J. Neurooncol. 2009, published online June 9, 2009
132. Matsumoto, S., et al., Cimetidine increases survival of colorectal cancer patients with high levels of sialyl LewisX and sialyl LewisA epitope expression on tumor cells. British J of Cancer, 2002, 86(2), 161167
133. Lefranc, F., et al., Combined cimetidine and temozolomide, compared with temozolomide alone: significant increases in survival in nude mice bearing U373 human glioblastoma multiforme orthotopic xenografts. J. of Neurosurgery, 2005, 102(4), 706714
134. Kesari, S., et al. Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. Neurooncology, 2008, 10 (3) 300308
135. Gilbert, M.R., Gonzalez,J., Hunter K., et al. A phase I factorial design study of dosedense temozolomide alone and in combination with thalidomide, Isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma. Neurooncology, 2010, 12 (11), 116772
136. Gilbert, M.R., Hess, K.R., Lagrone, L., et al. Randomized phase II 8arm factorial study of adjuvant dosedense temozolomide with permutations of thalidomide, Isotretinoin, and/or celecoxib for newly diagnosed glioblastoma. Proceedings of the 2012 AACP meeting, Abstract No. 2003
137. Balducci, M., Apicella, G., Mangiola, A., et al. Singlearm phase II study of conformal radiation therapy and temozolomide plus fractionated stereotactic conformal boost in highgrade gliomas: final report. Strahlentherapy Onkology, 2010, 186(10, 55864
138. Senior, K. Electrical killing fields for cancer cells. The Lancet Oncology, 2007, 8 (7), page 578
139. Stupp, R., Wong, E.T., Kanner A. A. et al. NovoTTF100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomized phase III trial of a novel treatment modality. European J. of Cancer, 2012, 48, 21922202
140. Ram, Z, Gutin, P. H., Stupp, R. Subgroup and quality of life analyses of the phase III clinical trial of NovoTTF100A versus best standard chemotherapy for recurrent glioblastoma. April 15, 2011 news release, International Medical News
141. Kirson, E. D., Schneiderman, R. S., Dbaly, V., et al Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields). BMC Medical Physics, 2009, 9 (1)
142. Rulseh, A. M., Keller, J., Kiener, J. et al. Longterm survival of patients suffering from glioblastoma multiforme treated with tumortreating fields. World Journal of Surgical Oncology, 2012, 10:220
143. Hayes, R. L., et al. Improved longterm survival after intracavitary interleukin2 and lymphokineactivated killer cells for adults with recurrent malignant glioma. Cancer, 1995, Vol. 76, pp. 840852
144. Dillman, R. O., Duma, C. M., Ellis, R. A., et al. Intralesional lymphokine activated killer cells as adjuvant therapy for primary glioblastoma. J. Immunother, 2009, 32(9), 91419
145. Salazar, A. M., et al. Longterm treatment of malignant gliomas with intramuscularly administered polyinosinicpolycytidylic acid stabilized with polylysine and carboxymethylcellulose: an open pilot study. Neurosurgery, 1996, Vol. 38, pp. 10961103.
Web abstract (atsidaro naujame lange)
146. Chang, S.M., et al. Phase II study of POLYICLC in recurrent anaplastic glioma A North American Brain Tumor Consortium Study. J. of Clin Oncology, 2006, 24, No. 18A Abstract No. 1550
147. Butowski, N., et al. A phase II clinical trial of polyICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC 0105). J. Neurooncol., 2009, 91: 175182
148. Rosenfeld, M. R., Chamberlain, M. C., Grossman, S. A., et al. A multi institutional phase II study of polyICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma. Neuro Oncol, 2010 Jul 8 (Epub ahead of print).
149. Yu, J. S., et al. Vaccination of malignant glioma patients with peptidepulsed dendritic cells elicits systemic cytotoxicity and intracranial Tcell infiltration. Cancer Research, 2001, 61, 842847
150-199
150. Yu, J. S., et al. Vaccination with tumor lysatepulsed dendritic cells elicits antigenspecific, cytotoxic T cells in patients with malignant glioma. Cancer Research, 2004, 64, 49734979
151. Wheeler, C. J., & Black, K. L. DCVaxBrain and DC vaccines in the treatment of GBM. Expert Opin. Investig. Drugs, 2009, 118(4), 509519
152. Wheeler, C. J., et al. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res., 2008, 68 (14), 595564
153. Prins, R. M., Soto, H., Konkankit, V., et al. Gene expression profile correlates with Tcell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clinical Cancer Research, 2011, 17(6)., 160315
154. Press release from Northwest Biotherapeutics, August 3, 2010
155. Rudnick, A., Hu. J., Luptrawan, A, et al. The final report of a phase I trial of surgical resection with biodegradable carmustine wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with glioblastoma. J. Clinical Oncology, 2012 (Suppl: abstract 2084)
156. Ardon, H., Van Gool, S. W., Verschuere, T. et al. Integration of autologous dendritic cellbased immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG2006 phase I/II trial. Cancer immunology and Immunotherapy, 2012, 61(11), 203344
157. Cho, DY, Yang,Wk, Lee, HC., et al. Adjuvant immunotherapy with wholecell lysate dendritic cells vaccine for glioblastoma: A phase II clinical trial. World Neurosurgery, 2012, 77(56), 73644
158. Phuphanich, S., Wheeler, C. J., Rudnick, J. D., et al. Phase I trial of multi epitopepulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunology and Immunotherapy, 2013, 62, 125135
159. Press Release from ImmunoCellular Therapeutics, Sept 12, 2011
160. Phuphanich, S., et al. Longterm remission over 5 years in patients with newly diagnosed glioblastoma treated with ICT107 vaccine: A followup study. (2013). Paper presented at the fourth quadrennial meeting of the World Federation of Neuro oncology, Abstract #IT015
161. Press Release from ImmunoCellular Therapeutics, Sept. 11, 2013
162. Okada, H., Kalinski, P., Ueda, R., et al. Induction of CD8+ Tcell responses against novel gliomaassociated antigen Peptides and clinical activity by vaccination with alphaType 1 polarized dendritic cells and polyinosinicpolycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma, J. Clin. Oncol., 2011, 29 (3), 33036
163. Bloch, Orin et al. "Heatshock protein peptide complex–96 vaccination for recurrent glioblastoma: a phase II, singlearm trial." Neurooncology 16.2 (2014): 274279.
Web article (atsidaro naujame lange)
164. Agenus Brain Cancer Vaccine Shows Extended Survival in Phase 2 Final Data Analysis. July 1, 2014 press release.
Web link (atsidaro naujame lange)
165. Jie, X., Hua, L., Jiang, W., et al. Application of a dendritic cell vaccine raised against heatshocked glioblastoma. Cell Biochem Biophys. 2011 Sept.11 (Epub ahead of print.
166. Sampson, J. H., Archer. G. E., Mitchell, D. A., et al. An epidermal growth factor receptor variant IIItargeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol. Cancer Ther. 2009, 8(10), 277379 167. Celldex Therapeutics Press Release, 6/1/2009
168. Pecora, A. L., et al. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. Journal of Clinical Oncology, Vol. 20, 22512266
169. Steiner, H. H., Bonsanto, M. M., Beckhove, P., et al. Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit. J. Clin. Oncol., 2004, 22(21). 427281
170. Germano, I. M., et al. Adenovirus/herpes simplexthymidine kinase/ganciclovir complex: preliminary results of a phase I trial in patients with recurrent malignant gliomas. Journal of Neurooncology, 2003, 65, 279289
171. Rampling, R. et al. Toxicity evaluation of replicationcompetent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Therapy, 2000, Vol. 7, 859866
172. Mitchell, D., et al. Efficacy of a phase II vaccine targeting Cytomegalovirus antigens in newly diagnosed GBM. Proceedings of the 2008 ASCO meeting, abstract # 2042
173. Stragliotto, G., Rahbar, A., Solberg, N. W., et al. Effects of valganciclovir as an addon therapy in patients with cytomegaloviruspositive glioblastoma: A randomized , doubleblind hypothesisgenerating study. International Journal of Cancer, 2013, 133, 120413
174. SöderbergNauclér, C., Rahbar, A., & Stragliotto, G., Survival in patients with glioblastoma receiving valganciclovir. New England Journal of Medicine, 2013, 369(10), 98586
175. SöderbergNauclér, C., Rashbar, A., & Stragliotto, G. . High survival in GBM patients receiving oral antiviral therapy against cytomegalovirus. Abstract MR029. Proceedings of the World Federation of Neurooncology, November 2013
176. Wolchok, J. D., Kluger H., Callahan, M.K., et al. Nivolumab plus ipilimumab in advanced melanoma. New England Journal of Medicine, 2013, 369(2), 12233
177. StarkVance, V., Bevacizumab (Avastin®) and CPT11 (Camptosar®) in the Treatment of Relapsed Malignant Glioma. Presentation at the meeting of the European Society of Neurooncology, April, 2005
178. Vredenburgh, JJ, et al., Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin Oncol. 2007, 25 (30) 47279
179. Nghiemphu, P., et al. A retrospective single institutional analysis of bevacizumab and chemotherapy versus nonbevacizumab treatments for recurrent glioblastoma. 2008 ASCO Proceedings, abstract # 2023
180. Wagner, S. A., et al. Update on survival from the original phase II trial of bevacizumab and irinotecan in recurrent malignant gliomas. 2008 ASCO Proceedings, Abstract # 2021
181. Avgeropoulos, N.,Avgeropoulos, G., ARiggs, G., & Reilly, C. Survival outcomes with lowdose bevacizumab compared to standard dose regimens in recurrent glioblastoma. Abstract # NO009, Proceedings of the 2013 meeting of the Society of
Neurooncology. Web abstract (atsidaro naujame lange)
182. Anderson, M. D., Puduvalli, V. K., Hamza, M. A., et al. Differences in outcome due to bevacizumab (BEV) discontinuation versus BEV failure in adults with glioblastoma. 2012 ASCO Proceedings, Abstract #2030
183. Friedman, H. S., Prados, M. D., Wen, P. Y., et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol., 2009, 27(228), 473340
184. Cloughesy, T., Vredenburgh, J. J., Day, B., et al. Updated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN study. 2010 ASCO meeting, Abstract #2008)
185. Maron, R., et al. Bevacizumab and daily temozolomide for recurrent glioblastoma multiforme (GBM)) 2008 ASCO Proceedings, Abstract # 2074
186. Desjardins, A., Reardon, D. A., Coan, A., et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer, 2011
187. Gutin, P. H., et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int. J. Radiation Oncol Biol Phys., 2009, 75(1): 156163
188. Park, K.J., Kano, H., Iyer, A., et al. Salvage gamma knife stereotactic radiosurgery followed by bevacizumab for recurrent glioblastoma multiforme: A casecontrol study. Journal of Neurooncology, 2012, 107(2), 32333
189. Sathornsumetee, S., Desjardins, A., Vredenburgh J. J., et al. Phase II trial of bevacizumab plus erlotinib for patients with recurrent malignant gliomas: Final results. 2010 ASCO Proceedings, Abstract #2055.
190. Brandes, A. A., et al. How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial. Neurology, 2004, 63 (7), 12811284
191. Rosenthal, M. A., et al. BCNU as second line therapy for recurrent highgrade glioma previously treated with temozolomide. Journal of Clinical Neuroscience, 2004, 11 (4), 374375
192. Schmidt, F., et al. PCV chemotherapy for recurrent glioblastoma. Neurology, 2006, 66 (4), 587589
193. Nobile, M. et al. Secondline PCV in recurrent or progressive glioblastomas: A phase II study. (2006), Abstracts from he Seventh Congress of the European Association for NeuroOncology, Abstract P167
194. Paccapelo, A., Lolli, I, Fabrini, M. G., et al. A retrospective pooled analysis of response patterns and risk factors in recurrent malignant glioma patients receiving a nitrosoureabased chemotherapy. J. Transl. Med., 2012, 1186 (May 14), 1479
195. Addeo, R. Carraglia, M., De Santi, M.S., et al. A new schedule of fotemustine in temozolomidepretreated patients with relapsing glioblastoma. J. of Neurooncology, 2011, 102(3), 41724
196. Yung, W.K., et al. Intravenous carboplatin for recurrent malignant glioma: a phase II study. Journal of Clinical Oncology, 1991, Vol. 9, pp. 860864
197. Friedman, H. S. et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. Journal of Clinical Oncology, 1999, Vol. 17, 15161525
198. Buckner, J. et al. A phase II trial of irinotecan (CPT11) in recurrent glioma. Proceedings of the American Society of Clinical Oncology, 2000, Abstract 679A
199. Chamberlain, M. C. Salvage chemotherapy with CPT11 for recurrent glioblastoma multiforme. Journal of Neurooncology, 2002, Vol. 56, 183188
200-249
200. Brandes, A.A., et al. Secondline chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after firstline temozolomide chemotherapy: A Phase II study of the Gruppo Italiano Cooperativo di NeuroOncologia (GICNO). J. of Clinical Oncology, 2004, 22(23), 47274734
201. Puduvalli, V., K., et al. Phase II trial of thalidomide in combination with irinotecan in adults with recurrent glioblastoma multiforme. 2005 Proceedings of the American Society for Clinical Oncology, Abstract #1524
202. Reardon, D.A., et al. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer, 2004, 103(2), 329338
203. Oberndorfer, S. et al. P450 enzyme inducing and nonenzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J of Neurooncology, 2005, 72 (3), 255260
204. Weller, M., Gorlia, T., Cairncross, J. G., et al. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology, 2011, 77, 115664
205. Kim, CY, Kim T., Han, J. H., et al. Survival benefit of Levetiracetam in glioblastoma treatment: A prospective singlearm and singlecenter study. Proceedings of the 2013 meeting of the Society of Neurooncology, Abstract #N070
206. Bobustuc, G. C., Baker, C. H. Limaye,A., et al. Levetiracetam enhances p53 mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide. Neurooncology, 2010, 12(9), 91727
207. Dashwood, R. H., & Ho, E. Dietary histone deacetylase inhibitors: from cells to mice to man. Seminars in Cancer Biol., 2007, 17 (5), 36369
208. Lonser, R. R., et al. Induction of glioblastoma multiforme in nonhuman primates after therapeutic doses of fractionated wholebrain radiation therapy. Journal of Neurosurgery, 2002, 97 (6), 13781389
209. Vitaz, T. W., et al. Brachytherapy for brain tumors. J. of NeuroOncology, 2005, 73, 7186
210. Souhami, l. et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: Report of Radiation Therapy Oncology Group 9305 protocol. Int. J. of Radiation Oncology, Biol Phys. 2004, 60(3), 853860
211. Welsh, J., et al. Gliasite brachytherapy boost as part of initial treatment of glioblastoma multiforme: a retrospective multiinstitutional pilot study. Int. J. Radiat. Oncol. Biol. Phys. 2007, 89) 1): 159165
212. Darakchiev, B. J., et al. Safety and efficacy of permanent iodine125 seed implants and carmustine wafers in patients with recurrent glioblastoma multiforme. J. Neurosurg, 2008, 108 (2), 236242
213. Balducci, Apicella, G., Manfrida, S., et al. Singlearm phase II study of conformal radiation therapy and temozolomide plus fractionated stereotactic conformal boost in highgrade gliomas: final report. Strahlenther. Onkol., 2010, 186(10), 55864
214. Ogawa, K. et al. Phase II trial of radiotherapy after hyperbaric oxygenation with multiagent chemotherapy (procarbazine, nimustine. And vincristine) for highgrade gliomas: Longterm results. International J. Rad. Oncol. Biol. Phys., 2011, 82 (2), pp. 73238
215. Jeyaapalan, S. A., Goldman, M., Donahue, J., et al. Treatment with Opaxio (paclitaxel Poligluex), temozolomide and radiotherapy results in encouraging progression free survival in patients with high grade malignant brain tumor. 2011 ASCO meeting, Abstract #2036
216. Mizumoto, M., et al. Phase I/II trial of hyperfractionated concomitant boost proton radiotherapy for supratentorial glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. 2009, Aug. 19 epub ahead of print
217. Cokgor, G. et al. Results of a Phase II trial in the treatment of recurrent patients with brain tumors treated with Iodine 131 antitenascin monoclonal antibody 81C6 via surgically created resection cavities. Proceedings of the American Society of Clinical Oncology, 2000, Abstract 628
218. Reardon, D. A., et al. Phase II trial of murine (131) Ilabeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. Journal of Clinical Oncology, 2002, Vol. 20, 13891397
219. Reardon, D., et al. An update on the effects of the effects of neuradiab on patients with newly diagnosed glioblastoma multiforme (GBM). Proceedings of the 2008 meeting of the Society for NeuroOncology, Abstract #MA104
220. Li, L., et al. Glioblastoma multiforme: A 20year experience using radio immunotherapy and temozolomide. Proceedings of the 2008 meeting of the Society for NeuroOncology, Abstract # IM26
221. Peregrine Pharmaceutical Press Release. Feb. 2, 2010: New Scientific Publication Highlights LongTerm Survival of Brain Cancer Patients Treated with Peregrine Pharmaceuticals’ Cotara ®.
222. Stylli, S. S., et al. Photodynamic therapy of highgrade glioma – longterm survival. J. Clin Neuroscience, 2005, 12 (4) 389398
223. Kostron, H. Photodynamic diagnosis and therapy and the brain. Methods Mol. Biol. 2010, 635, 261280
224. Muragaki, Y, Akimoto, J., Maruyama, T., et al. Phase II clinical study on intraoperative photodynamic therapy with talaporfin sodium and semiconductor lasers in patients with malignant brain tumors. Journal of Neurosurgery, 2013, 119, 84552
225. Lissoni, P., et al. Antiangiogenic activity of melatonin in advanced cancer patients. Neuroendocrinology Letters, 2001, Vol. 22, 4547
226. Lissoni, P., et al. Increased survival time in brain glioblastomas by a radio neuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone. Oncology, 1996, Vol. 53, pp. 4346
227. Lissoni, P., et al. Randomized study with the pineal hormone melatonin versus supportive care alone in advanced nonsmall cell lung cancer resistant to a firstline chemotherapy containing cisplatin. Oncology, 1992, Vol. 49, pp. 336339
228. Lissoni, P., et al. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumor patients with poor clinical status. European Journal of Cancer, 1999, Vol. 35, pp. 16881692
229. Lissoni, P. et al. Five year survival in metastatic nonsmall cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial. Journal of Pineal Research, 2003, Vol. 35, 1215
230. Lissoni, P., Biochemotherapy with standard chemotherapie plus the pineal hormone melatonin in the treatment of advanced solid neoplasms. Pathologie Biologie, 2007, 55, 201204
231. Lissoni, P., et al. Total pineal endocrine substitution therapy (TPEST) as a new neuroendocrine palliative treatment of untreatable metastatic solid tumor patients: a phase II study. Neuroendocrinology Letters, 2003, 24, 259262
232. Berk, L., et al. Randomized phase II trial of highdose melatonin and radiation therapy for RPA class 2 patients with brain metastases (RTOG 0119). Int. J. Radiat. Oncol. Biol. Phys., 2007, 68 (3) 85257
233. Hayakawa, K., et al. Effect of krestin (PSK) as adjuvant treatment on the prognosis after radical radiotherapy in patients with nonsmall cell lung cancer. Anticancer research, 1993, Vol. 13, pp. 18151820
234. Sakamoto, J., Morita, S. Oba, K. et al. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta analysis of centrally randomized controlled clinical trials. Cancer Immunology and Immunotherapy, 2006, 55(4), 404411
235. Kaneko, S., et al. Evaluation of radiation immunochemotherapy in the treatment of malignant glioma. Combined use of ACNU, VCR and PSK. Hokkaido Journal of Medical Science, 1983, Vol. 58, pp. 622630
236. Nanba, H. and Kubo, K. Effect of maitake Dfraction on cancer prevention. Annals of New York Academy of Sciences, 1997, Vol. 833, pp. 204207
237. Naidu, M. R., et al. Intratumoral gammalinolenic acid therapy of human gliomas. Prostaglandins Leukotrienes and Essential Fatty Acids, 1992, Vol. 45, pp. 181184
238. Das, U. N. et al. Local application of gammalinolenic acid in the treatment of human gliomas. Cancer Letters, 1994, Vol. 94, pp. 147155
239. Bakshi, A, et al. Gammalinolenic acid therapy of human gliomas. Nutrition, 2003, Vol. 19, 305309
240. Kenny, F. S. et al. Gamma linolenic acid with tamoxifen as primary therapy in breast cancer. International Journal of Cancer, 2000, Vol. 85, 643648
241. Palakurthi, S. S. et al. Inhibition of translation initiation mediates the anticancer effect of the n3 polyunsaturated fatty acid eicosapentaenoic acid. Cancer Research, 2000, Vol. 60, pp. 29192925
242. Gogos, C. A., et al. Dietary omega3 polyunsaturated fatty acids plus vitamin E restore immunodeficiency and prolong survival for severely ill patients with generalized malignancy: a randomized control trial. Cancer, 1998, Vol. 82, pp. 395 402
243. Hardman, W. E., et al. Three percent dietary fish oil concentrate increased efficacy of doxorubicin against MDAMB 231 breast cancer xenografts. Clinical Cancer Research, 2001, Vol. 71, pp. 20412049
244. Bougnoux, P., Hajjaji, N., Ferrasson, M. N. et al. Improving outcome of chemotherapy of metastatic breast cancer by docasahexaenoic acid: a phase II trial. Br. J Cancer, 2009, 101, 19781985
245. Murphy, R. A., Mourtzakis, M., Chu, QW. S., et al. Supplementation with fish oil increases firstline chemotherapy efficacy in patients with advanced nonsmall cell lung cancer. Cancer, 2011, 117(16), 377480
246. Van den Bemd, G. J., & Chang, G. T. Vitamin D and Vitamin D analogues in cancer treatment. Current Drug Targets, 2002, Vol. 3, 8594
247. Trouillas, P, et al. Redifferentiation therapy in brain tumors: longlasting complete regression of glioblastomas and an anaplastic astrocytoma under longterm 1alphahydroxycholecalciferol. Journal of Neurooncology, 51, 5766
248. Bollag, W. Experimental basis of cancer combination chemotherapy with retinoids, cytokines, 1, 25hydroxyvitamin D3, and analogs. Journal of Cellular Chemistry, 1994, Vol. 56, 427435
249. Bernardi, R. J., et al. Antiproliferative effects of 1alpha, 25dihydroxyvitamin D (3) and vitamin D analogs on tumorderived endothelial cells. Endocrinology, 2002, Vol. 143, 25082514
250-299
250. Danilenko, M., et al. Carnosic acid potentiates the antioxidant and prodifferentiation effects of 1alpha, 25dihydroxyvitamin D3 in leukemia cells but does not promote elevation of basal levels of intracellular calcium. Cancer Research, 2003, Vol. 63, 13251332
251. Chen, T. C., et al. The in vitro evaluation of 25hydroxyvitamin D3 and 19nor1 alpha, 25dihydroxyvitamin D2 as therapeutic agents for prostate cancer. Clinical Cancer Research, 2000, Vol. 6, 901908
252. Kumagai, T., et al. Vitamin D2 analog 19nor1, 25dihydroxyvitamin D2: antitumor activity against leukemia, myeloma and colon cancer cell lines. Journal of the National Cancer Institute, 2003, Vol. 95, 896905
253. Molnar, I., et al. 19nor1alpha, 25dihydroxyvitamin D (2) (paricalcitol): effects on clonal proliferation, differentiation, and apoptosis in human leukemia cell lines. Journal of Cancer Research and Clinical Oncology, 2003, Vol. 129, 3542 254. Woo, T.C.S, et al. Pilot study: Potential role of Vitamin D (Cholecalciferol) in patients with PSA relapse after definitive therapy. Nutrition and Cancer, 2005, 51(1), 3236
255. Da Fonseca. C. O., Schwartsmann, G., Fischer, J. et al. Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas. Surgical Neurology, 2008, 70, 25967
256. Da Fonseca, C. O., Simao, M., Lins, I. R., et al. Efficacy of monoterpene perillyl alcohol upon survival rate of patients with recurrent glioblastoma. J. Cancer Res. Clin. Oncol., 2010, epub, April 18
257. Aggarwal, B. B., & Shishodia, S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharm, 2006, 71, 13971421
258. Lazarevic, B., Boezelin, G., Diep, L. M., et al. Efficacy and safety of shortterm genistein intervention in patients with localized prostate cancer prior to radical prostatectomy: a randomized, placebocontrolled, doubleblind Phase 2 clinical trial. (2011), 63(6), 88998
259. Schroeder, F. H., Roobol, M. J., Boeve, EE. R., et al. Randomized doubleblind, placebocontrolled crossover study in men with prostate cancer and rising PSA: Effectiveness of a dietary supplement. European Urology, 2005, 922931
260. Dalais, F. S., Meliala, S., Wattanapenpaiboon, N., et al. Effect of a diet rich in phytoestrogens on prostatespecific antigen and sex hormones in men diagnosed with prostate cancer. Urology, 2004, 64(3), 51015
261. Peterson, G. Evaluation of the biochemical targets of genistein in tumor cells. Journal of Nutrition, (1995), 125,S784789
262. Khoshyomn, S., et al. Synergistic effect of genistein and BCNU in growth inhibition and cytotoxicity of glioblastoma cells. Journal of Neurooncology, 2002, Vol. 57, 193210
263. Ravindranath, M. H., Muthugounder. S., Presser, N., & Viswanathan, S. Anticancer therapeutic potential of soy isoflavone, genistein. Advances in Experimental Biology, 2004, 546, 121165
264. Kuroda, Y. and Hara, Y. Antimutagenic and anticarcinogenic activity of tea polyphenols. Mutation Research, 1999, Vol. 436, pp. 6997
265. Liao, J., et al. Inhibition of lung carcinogenesis and effects on angiogenesis and apoptosis in A/J mice by oral administration of green tea. Nutrition and Cancer, 2004, 48, 4453
266. Sherrington, A., et al. The sensitization of glioma cells to cisplatin and tamoxifen by the use of catechin. Mol. Biol. Rep., 2008, June 26 Epub ahead of print)
267. Chen, T. C., Wang, W., Golden E. B. et al. Green tea epigallocatechin enhances therapeutic efficacy of temozolomide in orthotopic mouse glioblastoma models. Cancer Letters, 2011, 302(2), 100108
268. Jatoi, A., et al. A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer, 2003, 97, 14421446
269. Shanafelt, T. D., Call, T. G., Zent, C. S., et al. Phase 2 trial of daily oral Polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia. Cancer, 2013, 119(2), 36370
270. Hoensch, H., Groh, B., Edier, L., & Kirch, W. Prospective cohort comparison of flavonoid treatment in patients with resected colorectal cancer to prevent recurrence. World Journal of Gastroenterology, 2008, 14(14), 218793
271. Golden, E. B., Lam, P. Y., Kardosh, A., et al. Green tea polyphenols block the anticancer effects of bortezomib and other boronic acidbased proteasome inhibitors. Blood, 2009, 113 (23), 592737
272. Aggarwal, B. B., et al. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Research, 2003, Vol. 23, 363398
273. Ryan, J. L., Heckler, C.E., Ling, M., et al. Curcumin for radiation dermatitis: a randomized doubleblind, placebo controlled clinical trial of thirty breast cancer patients. Radiation Research, 2013, 180(1), 3443
274. CruzCorrea, M., Shoskes, D. A., Sanchez, P., Zhao, R., et al. Combination treatment with curcumin and Quercetin of adenomas in familial adenomatous polyposis. Clinical Gastroenterology and Hepatology, 2006, 4(8), 103538
275. Ramasamy, K., and Agarwal, R., Multitargeted therapy of cancer by silymarin. Cancer Letters, 2008, 269(2), 35262
276. Singh, R. P., et al. Dietary feeding of silibinin inhibits advanced human prostate carcinoma growth in athymic nude mice and increases plasma insulinlike growth factorbinding protein3 levels. Cancer Research, 2002, Vol. 62, 30633069 277. Jiang, C., et al. Antiangiogenic potential of a cancer chemopreventive flavonoid antioxidant, silymarin: inhibition of key attributes of vascular endothelial cells and angiogenic cytokine secretion by cancer epithelial cells. Biochemical and Biophysical Research Communications, 2000, Vol. 276, 371378
278. Saller, R., et al. The use of silymarin in the treatment of liver diseases. Drugs, 2001, 61, 20352063
279. Bokemeyer, C., et al. Silibinin protects against cisplatininduced nephrotoxicity without compromising cisplatin or ifosfamide antitumor activity. British Journal of Cancer, 1996, Vol. 74, 20362041
280. Scambia, G., et al. Antiproliferative effect of silibinin on gynecological malignancies: synergism with cisplatin and doxorubicin. European Journal of Cancer, 1996, Vol. 32A, 877882
281. Kucuk, O. et al. Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. Cancer Epidemiology, Biomarkers and Prevention, 2001, Vol. 10, 861868
282. Ansari, M.S., & Gupta, N. P., A comparison of lycopene and orchidectomy vs. orchidectomy alone in the management of advanced prostate cancer. BJU Int. 2003, 92(4), 37578
283. Wang, C.J., et al. Inhibition of growth and development of the transplantable C6 glioma cells inoculated in rats by retinoids and carotenoids. Cancer Letters, 1989, 48, 135142
284. Karas, M., et al. Lycopene interferes with cell cycle progression and insulinlike growth factor I signaling in mammary cancer cells. Nutrition and Cancer, 2000, Vol. 36, 101111
285. Amir, H., et al. Lycopene and 1,25dihydroxyvitamin D3 cooperate in the inhibition of cell cycle progression and induction of differentiation in HL60 leukemia cells. Nutrition and Cancer, 1999, Vol. 33, 105112
286. Puri, T., et al., Role of natural lycopene and phytonutrients along with radiotherapy and chemotherapy in high grade gliomas. 2005 meeting of the American Society of Clinical Oncology, Abstract #1561
287. Fahey, J. W., et al. Broccoli sprouts: an exceptionally rich source of inducers of enzymes that protect against chemical carcinogens. Proceedings of the National Academy of Sciences, 1997, Vol. 94 (19), pp. 1036710372
288. Pantuck, A. J., Leppert, J.T. Zomorodian, N., et al. (2006). Phase II study of pomegranate juice for men with rising prostatespecific antigen following surgery or radiation for prostate cancer. Clin Cancer Res., 12(13), 401826
289. Zhang, R. X., et al. Laboratory studies of berberine used alone and in combination with 1,3bis (2chloroethyl)1nitrosourea to treat malignant brain tumors. Chinese Medical Journal, 1990, 103, 658665
290. Gansauge F, et al. The clinical efficacy of adjuvant systemic chemotherapy with gemcitabine and NSC631570 in advanced pancreatic cancer. Hepatogastroenterology. 2007 AprMay; 54(75): 91720.
291. LIN, C. J, Lee, C.C., Shih, T.Y., et al. Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy. Free Radical Biology & Medicine, 2012, 52(2), 37791
292. Tseng, S. H. et al. Resveratrol suppresses the angiogenesis and tumor growth of gliomas in rats. Clinical Cancer Research, 2004, 10, 2190220
293. Das, A., et al. Garlic compounds generate reactive oxygen species leading to activation of stress kinases and cysteine proteases for apoptosis in human glioblastoma T98G and U87MG cells.
294. Velasco, G., et al., et al. Hypothesis: cannabinoid therapy for treatment of gliomas? Neuropharmacology, 2004, 47, 315323
295. Blasquez, C., et al. Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Research, 2004, 64, 56175623
296. Torres S., Lorente, M., RodriguezFornes, F., et al. A combined preclinical therapy of cannabinoids and temozolomide against glioma. Brit. J Cancer, 2006, 95, 197203
297. Guzman, M. et al. A pilot clinical study of Delta (9)tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. British Journal of Cancer 2006, 95 (2), 197203
298. Kirste, S., Trier, M., Wehrie, S. J., et al. Boswellia serrate acts on cerebral edema in patients irradiated for brain tumors: A prospective, randomized, placebo controlled, doubleblind pilot trial. Cancer, 2011, 117(16), 378895
299. Jiang, H., Shang, X, Wu, H., et al. Combination treatment with resveratrol and sulforaphane induces apoptosis in human U251 glioma cells. Neurochem Res., 2009
300-349
300. Wang, Z., Desmoulin, S., Banerjee, S., et al. Synergistic effects of multiple natural products in pancreatic cells. Life Sciences, 2008, 83, 293300
301. Sarkar, F. H., & Li, Y. Using chemopreventive agents to enhance the efficacy of cancer therapy. Cancer Research, 2006,(2006, 66(7), 33473350
302. Landen, J. W., Hau, V., Wang, M., et al. Noscapine crosses the bloodbrain barrier and inhibits glioblastoma growth. Clin. Cancer Res., 2004, 10(15), 51875201
303. Berkson, B.M., Rubin, D. M., & Berkson, A. J. Revisiting the ALA/N (alpha lipoic acid/lowdose naltrexone) protocol for people with metastatic and nonmetastatic pancreatic cancer: a report of 3 new cases. Integr Cancer Ther. (2009), 8(4), 41622
304. Rosenfeld, Myrna R et al. "A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme." Autophagy 10.8 (2014): 13591368.
Web abstract (atsidaro naujame lange)
305. Jutten, Barry et al. "EGFR overexpressing cells and tumors are dependent on autophagy for growth and survival." Radiotherapy and Oncology 108.3 (2013): 479483.
Web abstract (atsidaro naujame lange)
306. Kast, Richard E, Georg KarpelMassler, and MarcEric Halatsch. "CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide." Oncotarget 5.18 (2014): 8052.
Web article (atsidaro naujame lange)
307. PenasPrado, Marta et al. "Randomized phase II adjuvant factorial study of dosedense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma." Neurooncology (2014): nou155.
Web abstract (atsidaro naujame lange)
308. Mrugala, Maciej M et al. "Clinical Practice Experience With NovoTTF100A™ System for Glioblastoma: The Patient Registry Dataset (PRiDe)." Seminars in oncology 31 Oct. 2014: S4S13.
Web article (atsidaro naujame lange)
309. ImmunoCellular Therapeutics Presents Updated ICT107 Phase II Data in Patients with Newly Diagnosed Glioblastoma at the 2014 ASCO Annual Meeting
Web release (atsidaro naujame lange)
310. Piccioni, David E et al. "Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy." Neurooncology 16.6 (2014): 815822.
Web abstract (atsidaro naujame lange)
311. Hamza, Mohamed A et al. “Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma.” J Neurooncol. 2014 Aug;119(1):13540.
Web article (atsidaro naujame lange)
312. Taal, Walter et al. "Singleagent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial." The Lancet Oncology 15.9 (2014): 943953.
Web abstract (atsidaro naujame lange)
313. Cominelli, Manuela et al. "EGFR Amplified and Overexpressing Glioblastomas and Association with Better Response to Adjuvant Metronomic Temozolomide." Journal of the National Cancer Institute 107.5 (2015): djv041.
Web abstract (atsidaro naujame lange)
314. D’Elia, Alessandro, et al. "Extended Daily Schedule of Temozolomide in Recurrent Glioblastoma: SingleInstitution Report on a Series of 43 Patients."Journal of Cancer Therapy 2014 (2014).
Web article (atsidaro naujame lange)
315. Wakabayashi, Toshihiko et al. "AT58JCOG0911 INTEGRA TRIAL: A RANDOMIZED SCREENING PHASE II TRIAL OF CHEMORADIOTHERAPY WITH INTERFERONβ PLUS TEMOZOLOMIDE VERSUS CHEMORADIOTHERAPY WITH TEMOZOLOMIDE ALONE FOR NEWLYDIAGNOSED GLIOBLASTOMA." NeuroOncology 16.suppl 5 (2014): v21v21.
Web abstract (atsidaro naujame lange)
316. Recchia, Francesco et al. "Interleukin2 and 13cis retinoic acid as maintenance therapy in advanced ovarian cancer." International journal of oncology 27.4 (2005): 10391046.
Web abstract (atsidaro naujame lange)
317. Hassler, Marco Ronald et al. "Thalidomide as Palliative Treatment in Patients with Advanced Secondary Glioblastoma." Oncology 88.3 (2015): 173179.
Web abstract (atsidaro naujame lange)
318. Barker, Christopher A et al. "Valproic acid use during radiation therapy for glioblastoma associated with improved survival." International Journal of Radiation Oncology* Biology* Physics 86.3 (2013): 504509.
Web abstract (atsidaro naujame lange)
319. Krauze, Andra V., Sten D. Myrehaug, Michael G. Chang, Diane J. Holdford, Sharon Smith, Joanna Shih, Philip J. Tofilon, Howard A. Fine, and Kevin Camphausen. "A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma." International Journal of Radiation Oncology*Biology*Physics: 98692.
Web abstract (atsidaro naujame lange)
320. Mitchell, Duane A et al. "Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients." Nature 519.7543 (2015): 366369.
Web abstract (atsidaro naujame lange)
321. Schuster, James et al. "A phase II, multicenter trial of rindopepimut (CDX110) in newly diagnosed glioblastoma: the ACT III study." Neurooncology (2015): nou348.
Web abstract (atsidaro naujame lange)
322. Brandes, Alba A et al. "AT11 FINAL RESULTS FROM THE RANDOMIZED PHASE II TRIAL AVAREG (ML25739) WITH BEVACIZUMAB (BEV) OR FOTEMUSTINE (FTM) IN RECURRENT GBM." NeuroOncology 16.suppl 5 (2014): v10v10.
Web abstract (atsidaro naujame lange)
323. Kim, YoungHoon, Tackeun Kim, JinDeok Joo, Jung Ho Han, Yu Jung Kim, In Ah Kim, ChangHo Yun, and ChaeYong Kim. "Survival Benefit of Levetiracetam in Patients Treated with Concomitant Chemoradiotherapy and Adjuvant Chemotherapy with Temozolomide for Glioblastoma Multiforme." Cancer.
Web abstract (atsidaro naujame lange)
324. Pitter, Kenneth L et al. "Corticosteroids compromise survival in glioblastoma." Brain (2016): aww046.
325. Blumenthal, Deborah T et al. "ATCT08THE IMPACT OF EXTENDED ADJUVANT TEMOZOLOMIDE IN NEWLYDIAGNOSED GLIOBLASTOMA: A SECONDARY ANALYSIS OF EORTC AND NRG ONCOLOGY/RTOG." NeuroOncology 17.suppl 5
(2015): v2v2. Web abstract (atsidaro naujame lange)
326. Ikuta, Soko et al. "ATPS38ASSESSMENT OF OPTIMIZED THERAPEUTIC TERM WITH TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA."
NeuroOncology 17.suppl 5 (2015): v26v26. Web abstract (atsidaro naujame lange) (atsidaro naujame lange)
327. Stupp, Roger et al. "Maintenance therapy with tumortreating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial." Jama 314.23 (2015): 25352543.
328. Carpentier, AF et al. "Steroid-sparing effects of angiotensin-II inhibitors in glioblastoma patients." European journal of neurology 19.10 (2012): 13371342.
329. Kourilsky, Antoine et al. "Impact of AngiotensinII receptor blockers on vasogenic edema in glioblastoma patients." Journal of neurology 263.3 (2016): 524530.
330. Januel, E et al. "Impact of renin-angiotensin system blockade on clinical outcome in glioblastoma." European Journal of Neurology 22.9 (2015): 13041309.
331. Michel, Martin C et al. "A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists." Pharmacological reviews 65.2 (2013): 809848.
332. Huang, Jiayi et al. "A phase I study to repurpose disulfiram in combination with temozolomide to treat newly diagnosed glioblastoma after chemoradiotherapy." Journal of neurooncology (2016): 18.
333. Cole, Steven W, and Anil K Sood. "Molecular pathways: betaadrenergic signaling in cancer." Clinical cancer research 18.5 (2012): 12011206.
334. Cole, Steven W et al. "Sympathetic nervous system regulation of the tumour microenvironment." Nature Reviews Cancer 15.9 (2015): 563572.
335. Chang, PingYing et al. "Propranolol reduces Cancer risk: a populationbased cohort study." Medicine 94.27 (2015).
336. Watkins, Jack L et al. "Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer." Cancer 121.19 (2015): 34443451.
337. Happold, Caroline et al. "Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma." Journal of Clinical Oncology (2016): JCO636563.
338. Fay, Michael F et al. "Valproate in adjuvant glioblastoma treatment." Journal of Clinical Oncology (2016): JCO672162.
339. Bloch, Orin et al. "Newly diagnosed glioblastoma patients treated with an autologous heat shock protein peptide vaccine: PDL1 expression and response to therapy." ASCO Annual Meeting Proceedings 20 May. 2015: 2011.
340. Reardon, David A et al. "ReACT: longterm survival from a. randomized phase II study of rindopepimut (CDX110) plus bevacizumab in relapsed. glioblastoma." Neuro Oncol 17.suppl 5 (2015): v109.
341. Hashimoto, Naoya et al. "Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response." Cancer Immunology, Immunotherapy 64.6 (2015): 707716.
342. Hashimoto, Naoya et al. "IMCT09 WT1 peptide vaccination for gliomas; survivals, biomarkers and response assessment." NeuroOncology 17.suppl 5 (2015): v109v109.
343. Geletneky, Karsten et al. "ATNT07 FAVORABLE RESPONSE OF PATIENTS WITH GLIOBLASTOMA AT SECOND OR THIRD RECURRENCE TO REPEATED INJECTION OF ONCOLYTIC PARVOVIRUS H1 IN COMBINATION WITH BEVACICUMAB." NeuroOncology 17.suppl 5 (2015): v11v11.
344. Cloughesy, Timothy F et al. "Phase 1 trial of vocimagene amiretrorepvec and 5fluorocytosine for recurrent highgrade glioma." Science translational medicine 8.341 (2016): 341ra75341ra75.
345. Nitta, Masayuki et al. "ATCT24 Role of photodynamic therapy (PDT) for glioblastoma." NeuroOncology 17.suppl 5 (2015): v6v7.
346. Chinot, Olivier L et al. "Upfront bevacizumab may extend survival for glioblastoma patients who do not receive secondline therapy: an exploratory analysis of AVAglio." Neurooncology (2016): now046.
347. Levin, Victor A et al. "Impact of bevacizumab administered dose on overall survival of patients with progressive glioblastoma." Journal of neurooncology 122.1 (2015): 145150.
348. Blumenthal, D. T., L. Mendel, and F. Bokstein. "The Optimal Regimen of Bevacizumab for Recurrent Glioblastoma: Does Dose Matter?" J Neurooncol Journal of NeuroOncology 127.3 (2015): 493502.
349. Hercbergs, Aleck A et al. "Propylthiouracilinduced chemical hypothyroidism with highdose tamoxifen prolongs survival in recurrent high grade glioma: a phase I/II study." Anticancer research 23.1B (2002): 617626.
350-399
350. Bergh, Joel J., HungYun Lin, Lawrence Lansing, Seema N. Mohamed, Faith B. Davis, Shaker Mousa, and Paul J. Davis. "Integrin α V β 3 Contains a Cell Surface Receptor Site for Thyroid Hormone That Is Linked to Activation of MitogenActivated Protein Kinase and Induction of Angiogenesis." Endocrinology 146.7 (2005): 2864871. Web.
351. Hercbergs, Aleck et al. "Medically induced euthyroid hypothyroxinemia may extend survival in compassionate need cancer patients: an observational study." The oncologist 20.1 (2015): 7276.
352. AshurFabian, Osnat et al. "Longterm response in highgrade optic glioma treated with medically induced hypothyroidism and carboplatin: a case report and review of the literature." Anticancer drugs 24.3 (2013): 315323.
353. Nasrollahzadeh, Javad et al. "The influence of feeding linoleic, gammalinolenic and docosahexaenoic acid rich oils on rat brain tumor fatty acids composition and fatty acid binding protein 7 mRNA expression." Lipids in health and disease 7.1 (2008): 1.
354. Guest, Jade et al. "Relationship between central and peripheral fatty acids in humans." Lipids in health and disease 12.1 (2013): 1.